Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 27, 309–311 (1 April 2009) | doi:10.1038/nbt0409-309
New relief for gout
Abstract
On February 16, the US Food and Drug Administration (FDA) approved Deerfield, Illinois–based Takeda Pharmaceuticals' drug Uloric (febuxostat), an oral inhibitor of xanthine oxidase, for the chronic management of gout, and not far behind are three others (Table 1). Four new drugs after 40 years of drought may sound like an excess of riches or at least a tough battle for market share.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
